<DOC>
	<DOC>NCT00297063</DOC>
	<brief_summary>This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.</brief_summary>
	<brief_title>BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion criteria: Type 2 diabetes mellitus. Managed by diet therapy. Must have adequate blood, liver and kidney function. Exclusion criteria: Serious cardiovascular disease or serious hepatic disease.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>vandia</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>diabetes;</keyword>
</DOC>